This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

ghs 2018 session recordings


Still thinking about that session from GHS 2018? Or were you not able to make it in person?

Watch the specialists in your field discuss and debrief the highlights of GHS 2018, learn about the latest advances in research and patient management by browsing the complete catalogue of GHS 2018 session recordings.

The 16th ISVHLD Global Hepatitis Summit 2018 recordings represent the best the world has to offer in the hepatology sector. Sessions and speakers include:

  • Plenary Sessions
    • WHO Elimination Targets with John Ward & Julio Montaner
    • Immune Regulation in Viral Hepatitis with Robert Thimme & Adam Gehring
    • The Future of HBV Cure with Poonam Mishra & Harry Janssen
    • HCV Treatment - Remaining Challenges with Jordan Feld & Norah Terrault 

  • Basic Science
    • HBV Virology with Fabien Zoulim & John Tavis
    • HBV Immunology with Barbara Rehermann & Patrick Kennedy
    • Viral Hepatitis Models with Massimo Levrero & Sonya MacParland 

  • Clinical
    • New Biomarkers & Endpoints in HBV with Blaine Hollinger & Seng Gee Lim
    • HBV Emerging Therapies with Geoff Dusheiko & Ray Schinazi 
    • HCV Therapy with MArk Sulkowski & Antonio Craxi 

  • Public Health
    • Elimination Strategies: Micro vs National Elimination with Natasha Martin & Gottfried Hirnschall
    • P.O.C. & Testing Developments with Margaret Hellard & Marina Klein
    • Vaccination in HAV/HEV/HBV with Brian McMahon & Maud Lemoine

  • Oral Abstracts 
  1. Global scale-up of hepatitis C interventions will reduce burden but not eliminate the disease
  2. Early Hepatitis C Virus and IP-10 Kinetics During DAA Treatment with Sofosbuvir, Velpatasvir, and Voxileprevir in HCV Mono-infected and HIV/HCV Co-infected Persons
  3. Extension of Hepatitis C Screening, Diagnosis and Treatment into the Community: A Low Cost, Point of Care, Test and Treat Model for Pakistan
  4. Drug and alcohol use patterns during and following treatment with sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use: Insights from trajectory analyses
  5. A decisive role of target cells during antiviral immunity in the liver
  6. HEPATITIS E - PROFILE AND PREDICTORS OF MORTALITY : INDIAN EXPERIENCE
  7. Updated Follow-up Analysis in the REP 401 Protocol: Treatment of HBeAg Negative Chronic HBV Infection with REP 2139 or REP 2165, Tenofovir Disoproxil Fumarate and Pegylated Interferon α-2a
  8. Immunological Phenotyping of HLA-restricted HBV specific T Cell Responses In Dually Humanized Mice.
  9. Increasing hepatitis C testing uptake with point of care testing from the needle and syringe exchange desk – lessons learned from the Rapid-EC Feasibility Study.
  10. Genetic variability of hepatitis C quasi-species in early infection
  11. Pathways to ensure universal and affordable access to hepatitis C treatment
  12. Antiviral CD4+ but not CD8+ T Cell Immunity is Required to Prevent Hepatitis E Virus Persistence.
  13. Interferon-gamma pathway is activated in a chronically HBV infected chimpanzee that controls HBV following ARC-520 RNAi treatment
  14. Identification of ISG20 as the Nuclease involved in Interferon-induced Decline of HBV cccDNA
  15. An Immunochromatographic Test for measurement of Alanine Aminotransferase 1 (ALT1) at Point-of-Care
  16. Association between liver fibrosis and HEV seroprevalence among HIV-positive individuals in Nepal
  17. Differential peripheral immune responses during DAA treatment in HCV patients that develop HCC
  18. Sex-linked Variation in Immune Cell Composition and Inflammatory Potential in the Human Liver
  19. A novel CRISPR/Cas9-based approach to transient activation of intracellular host restriction factors results in strong suppression of hepatitis B virus and degradation of cccDNA
  20. Analysis of AST to Platelet Ratio Index (APRI) for Determining Eligibility for 8 Weeks of Glecaprevir/Pibrentasvir
  21. Hepatic Steatosis Measured by Elastography among HIV-Infected and HIV-Uninfected People who Inject Drugs (PWID) 
  22. Correlates of Hepatic Fibrosis among HIV-Infected Individuals from an Urban Infectious Disease Clinic in East Africa
  23. Are hepatitis delta virus (HDV) genotypes important to determine the disease progression and therapy responses?
  24. HCC recurrence in HCV patients after liver transplantation in the DAA treatment era: SiLVER Study subgroup analysis reveals sirolimus treatment in combination with CNIs is an excellent treatment option
  25. Investigation of the Molecular Mechanisms that Determine Isolate-Specific Differences in Neutralization Sensitivity of HCV
  26. Directly Acting Antiviral HCV Therapy is Safe and Effective in Patients with Advanced Cirrhosis: Real World Experience from the HCV-TARGET Cohort
  27. Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B
  28. A Novel Gene Immunotherapy for Chronic HBV and HDV: Blocking Viral Entry by Neutralizing PreS1 Antibodies
  29. Comparison of event-free survival between DAA and IFN-based antiviral therapy for HCV, adjusted for disease severity
  30. Combination Treatment of a TLR7 Agonist RO7020531 and a Capsid Assembly Modulator RO7049389 Achieved Sustainable Viral Load Suppression and HBsAg Loss in an AAV-HBV Mouse Model 
  31. Effectiveness of synergy of HIV prevention and National Hepatitis C Elimination programs in Georgia
  32. Evaluation of renal and bone and safety in patients with CHB and chronic kidney disease treated with tenofovir alafenamide (TAF) in post liver transplantation
  33. Safety and efficacy at 1 year after switching from tenofovir disoproxil fumurate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use
  34. Economic Analysis of Egypt’s Hepatitis C Control Policies
  35. HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B and its relation to other serum viral biomarkers
  36. Genotype 5 HCV – patient characteristics, resistance mutations and treatment outcomes
  37. Prevention and care cascade for hepatitis C among people who inject drugs in British Columbia, Canada
  38. Cost-effectiveness of the controlled temperature chain for the hepatitis B birth dose vaccine in a variety of global settings
  39. Effects of Pioglitazone and L-ornithine-L-aspartate Long Therapy on NASH course in Patients with Diabetes Mellitus Type 2
  40. The Global Impact of Direct Acting Antivirals on Hepatitis C Virus burden: A ten-year forecast
  41. Kupffer Cells Coordinate Interferon-lambda Driven Inflammation
  42. Hepatitis A Outbreak in Men Having Sex with Men in Israel 2017: Environmental and Clinical Surveillance
  43. Elimination of hepatitis C as a public health threat. The Treatment as Prevention (TraP HepC) program in Iceland, milestones and remaining challenges
  44. Histologic Predictors of Liver-Related Outcomes and Mortality in Patients with Chronic Hepatitis B and Non-Alcoholic Fatty Liver Disease
  45. Clinical and virological predictors of response after antiviral therapy interruption in HBeAg-negative chronic hepatitis B
  46. Sustained off-treatment response is associated with HBsAg loss following Nucleos(t)ide Analogue induced HBeAg seroconversion
  47. Early function modulation and reprogramming of liver resident and infiltrating macrophages promote the establishment of HBV infection
  48. Expansion of HCV-specific T cells with a follicular T helper cell phenotype after DAA mediated antigen removal
  49. A Phase 2 Dose-Optimization Study of Lonafarnib with Ritonavir for the Treatment of Chronic Delta Hepatitis—Analysis from the LOWR HDV-2 Study Using the Robogene® Real-Time qPCR HDV RNA Assay.
  50. Origin and function of secreted ORF2 in hepatitis E virus infection
  51. Is Hepatitis C Elimination Possible Among HIV-infected Population in Canada?

 

For $149 CAD plus tax you can enjoy the conference content on your desktop, laptop, tablet or phone. You'll have:

  • Audio of the presentations synchronized with the presentation slides
  • Online access for viewing anywhere, at any time

Order online by contacting: INFO@GLOBAL-HEPATITIS.COM